Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP
- Sponsor
- Rigel Pharmaceuticals
- Study ID
- NCT03363334
- Status
- No Longer Available
Conditions
- Immune Thrombocytopenic Purpura
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Fostamatinib disodium 100 mg — DRUGFostamatinib Disodium tablet 100 mg PO bid (morning and evening)
- Fostamatinib disodium 150 mg — DRUGFostamatinib Disodium tablet 150 mg PO bid (morning and evening)
Study Details
C-935788-055 is an open-label, multi-center, expanded access (EAP) study.
Key Dates
- Status verified
- Jun 2018
Related Studies
- Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic PurpuraPHASE1 · Recruiting · New York Medical College · Vahalla, New York